Cargando…
83. Infectious Outcomes of CAR T-cell Therapy: Longitudinal Follow Up and Risk Stratification
BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 is increasingly utilized in the treatment of a variety of hematologic malignancies. While efficacious, this therapy is associated with prolonged cytopenias and immunosuppression. Open questions remain regarding the distributio...
Autores principales: | Czapka, Michael, Riedell, Peter A, Pisano, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752853/ http://dx.doi.org/10.1093/ofid/ofac492.008 |
Ejemplares similares
-
2721. Respiratory Virus Infections Following CAR T-cell Therapy: Risk Factors and Outcomes
por: Powell, Natasha, et al.
Publicado: (2023) -
925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy
por: Trottier, Caitlin, et al.
Publicado: (2021) -
O8.3. CLINICAL AND FUNCTIONAL OUTCOMES IN YOUNG ADULTHOOD OF CHILDREN WITH PSYCHOTIC SYMPTOMS: A LONGITUDINAL TWIN COHORT STUDY
por: Trotta, Antonella, et al.
Publicado: (2018) -
2694. Infectious Complications in CAR-T Cell Therapy Recipients: A Systematic Review and Meta-Analysis
por: Banegas, Marcela, et al.
Publicado: (2023) -
1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
por: Garner, Will, et al.
Publicado: (2020)